Risperidone is a serotonin 5-HT2 receptor blocker, P-Glycoprotein inhibitor and potent dopamine D2 receptor antagonist, with Ki values of 4.8, 5.9nM for 5-HT2A and dopamine D2 receptor, respectively[1]. 5-HT2 receptor and dopamine D2 receptor are both important neurotransmitter receptors involved in modulating emotional and cognitive functions as well as motor and reward processes, and are closely related to the pathogenesis of various neuropsychiatric disorders[2]. Risperidone is commonly used in the research of diseases such as schizophrenia and bipolar disorder[3].
In vitro, treatment of dendritic cells with Risperidone(10⁻⁸ to 10⁻⁵M; 4 days) increases IL-10 and MDC production, decreases IP-10 and IL-12, and induces TNF-α release[4]. Treatment of MC3T3-E1 cells with Risperidone(10-200μM; 48h) inhibited cell proliferation and induced apoptosis in a dose-dependent manner, downregulated BGP, collagen 1, OPG, and RANKL, and upregulated TNF-α gene and protein expression[5].
In vivo, Risperidone (1mg/kg/day; p.o.; 56 days) increased body weight, fatty liver scores, serum ALT/AST, triglycerides, BUN, and creatinine, decreased GLUT4 expression and Akt phosphorylation, and induced renal inflammation in high-fat diet-fed C57BL/6J mice[6]. Risperidone (1-4mg/kg/day; i.g.; 7 days) reversed Aβ1-42-induced cognitive deficits, reduced hippocampal and cortical Aβ1-42, BACE1 and p-Tau levels, and inhibited neuronal apoptosis in ICR mice[7].
References:
[1] Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology (Berl). 1993;110(3):265-272.
[2] Remington G, Kapur S. D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. J Clin Psychiatry. 1999;60 Suppl 10:15-19.
[3] Bhat AA, Gupta G, Afzal O, et al. Neuropharmacological effect of risperidone: From chemistry to medicine. Chem Biol Interact. 2023;369:110296.
[4] Chen ML, Tsai TC, Wang LK, et al. Risperidone modulates the cytokine and chemokine release of dendritic cells and induces TNF-α-directed cell apoptosis in neutrophils. Int Immunopharmacol. 2012;12(1):197-204.
[5] Zheng L, Yang L, Zhao X, Long N, Li P, Wang Y. Effect of risperidone on proliferation and apoptosis of MC3T3-E1 cells. Braz J Med Biol Res. 2019;52(3):e8098.
[6] Tsai HP, Hou PH, Mao FC, et al. Risperidone Exacerbates Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Renal Impairment in Obese Mice. Int J Mol Sci. 2021;22(1):409.
[7] Wu L, Feng X, Li T, Sun B, Khan MZ, He L. Risperidone ameliorated Aβ1-42-induced cognitive and hippocampal synaptic impairments in mice. Behav Brain Res. 2017;322(Pt A):145-156.
Risperidone是一种5-羟色胺5-HT₂受体阻断剂、P-糖蛋白抑制剂和强效多巴胺D₂受体拮抗剂,对5-HT₂A和多巴胺D₂受体的Ki值分别为4.8nM和5.9nM[1]。5-HT₂受体和多巴胺D₂受体均是重要的神经递质受体,参与调节情绪、认知功能以及运动和奖赏过程,与多种神经精神疾病的发病机制密切相关[2]。Risperidone常用于精神分裂症和双相情感障碍等疾病的研究[3]。
在体外实验中,Risperidone(10-8至10-5M;4天)处理树突细胞可增加IL-10和MDC的产生,降低IP-10和IL-12的水平,并诱导TNF-α的释放[4]。Risperidone(10-200μM;处理48小时)可剂量依赖性地抑制MC3T3-E1细胞的增殖并诱导其凋亡,下调BGP、胶原蛋白1、OPG和RANKL的表达,同时上调TNF-α的基因和蛋白表达[5]。
在体内实验中,Risperidone(1mg/kg/天;口服;56天)可增加高脂饮食喂养的C57BL/6J小鼠的体重、脂肪肝评分、血清ALT/AST、甘油三酯、BUN和肌酐水平,降低GLUT4表达和Akt磷酸化水平,并诱导肾脏炎症[6]。Risperidone(1-4mg/kg/天;灌胃;7天)可逆转Aβ1-42诱导ICR小鼠的认知障碍,降低海马和皮质Aβ1-42、BACE1和p-Tau的水平,并抑制神经元凋亡[7]。
















